1.Xanthones from Garcinia pedunculata and Garcinia nujiangensis and their anti-inflammatory activity.
Xiaojie FAN ; Yufeng JIA ; Jiaxin GUO ; Jinyuan YANG ; Dahong LI ; Huiming HUA
Chinese Journal of Natural Medicines (English Ed.) 2025;23(2):225-233
Ten novel xanthones, garpedunxanthones A-G (1-5, 6a/6b, 7a/7b) and nujiangxanthone Q (8), along with sixteen known analogs (9-24), were isolated from Garcinia pedunculata and G. nujiangensis. Their structures were elucidated through high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) data, comprehensive nuclear magnetic resonance (NMR) spectroscopic analyses, and electronic circular dichroism (ECD) calculations. All compounds without cytotoxicity were assessed for anti-inflammatory properties by measuring the inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW264.7 cells. Structure-activity relationships are also discussed. Compounds 7b, 19, and 21 exhibited significant anti-inflammatory activity with IC50 values of 16.44 ± 0.69, 14.28 ± 0.78, and 10.67 ± 3.28 μmol·L-1, respectively. Enzyme-linked immunosorbent assay (ELISA) demonstrated that compounds 7b, 19, and 21 inhibited the expression of pro-inflammatory cytokines TNF-α and IL-6 in a dose-dependent manner. The inhibitory effect of compound 21 on IL-6 at 20 μmol·L-1 was comparable to that of the positive control. In network pharmacology studies, potential targets of compounds and inflammation were identified from PharmMapper and GeneCards databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that the overlapped targets were intricately associated with major pathogenic processes linked to inflammation, including positive regulation of mitogen-activated protein kinase (MAPK) cascade, protein kinase activity, NO synthase regulator activity, MAPK signaling pathway, and EGFR tyrosine kinase inhibitor resistance.
Xanthones/therapeutic use*
;
Garcinia
;
Anti-Inflammatory Agents/therapeutic use*
;
Plant Preparations/therapeutic use*
;
Structure-Activity Relationship
;
Nitric Oxide/metabolism*
;
RAW 264.7 Cells
;
Animals
;
Mice
;
Enzyme-Linked Immunosorbent Assay
;
Mitogen-Activated Protein Kinase Kinases/metabolism*
;
Circular Dichroism
2.Prevalence and molecular detection of human Cryptosporidium infections: a review
Yufeng LIU ; Hua LIU ; Kerong LI ; Yuhua LIU
Chinese Journal of Schistosomiasis Control 2024;36(1):105-110
Cryptosporidium is an important intestinal parasite that is mainly transmitted through the fecal-oral route. Human infection may occur following ingestion of water and food contaminated by Cryptosporidium oocysts, and children and immunocompromised individuals are at a high risk of infections. The main symptoms of Cryptosporidium infections include diarrhea, vomiting, malnutrition, and even death. Because of high sensitivity and rapid procedures, molecular tests are helpful for the diagnosis of cryptosporidiosis and may reduce the public health risk of cryptosporidiosis. This review summarizes the advances in the latest prevalence and molecular detection of human Cryptosporidium infections during recent years.
3.Analysis of clinical and pathological characteristics of drug-induced live injury based on hepatotoxicity injury patterns
Honghai XU ; Shiwei ZHU ; Hui ZHANG ; Yufeng GAO ; Hua WANG
Chinese Journal of Clinical and Experimental Pathology 2024;40(2):172-178
Purpose To explore the clinical and pathologi-cal features and the relationships between pathological features and drugs of patients with drug-induced liver injury(DILI)based on the hepatotoxicity injury patterns.Methods The clin-ical data,laboratory indicators,drugs,and liver biopsy of 50 cases of DILI were collected,the expression of CK19 was detec-ted by immunohistochemistry EnVision two-step method,and the reticular scaffold of liver tissue was displayed by Reticular fiber staining.Results Among the 50 patients with DILI,there were 29 cases of hepatocellular DILI,11 cases of cholestatic DILI,and 10 cases of mixed DILI,respectively,with the hepatocellu-lar DILI accounting for the highest proportion(58%).7 catego-ries of drugs induced DILI,with herbal ranking first(52%).Different types of drugs could cause different types of DILI,with herbal induced 17 cases hepatocellular DILI(58.62%)and an-ti-infectious and anticancer drugs induced all 3 cases cholestatic DILI(27.27%).Different types of DILI displayed various pathological characteristics.Hepatocellular congestion,feathery degeneration,and small bile duct thrombosis primarily occur in cholestasis and mixed DILI,while bridging necrosis,sub-large and large necrosis were mainly seen in hepatocellular DILI.Conclusion Based on hepatotoxicity injury patterns,DILI ex-hibits a variety of clinical and pathological characteristics,and there is some relationship between pathological characteristics and drugs.Liver puncture pathological biopsy plays an important role in improving the diagnosis and treatment of DILI.
4.The evaluation value of serum PTX3 and CK-MB levels on volume load in patients with chronic decompensated heart failure
Mingshan CAO ; Chundi WANG ; Xiaoqian HU ; Linghui MENG ; Yufeng WU ; Huan LIU ; Hua YANG
Journal of Chinese Physician 2024;26(1):87-92
Objective:To explore the evaluation value of serum levels of positive pentameric protein 3 (PTX3) and creatine kinase isoenzyme MB (CK-MB) on volume load in patients with chronic decompensated heart failure (CDHF).Methods:A total of 300 CDHF patients who visited the Xingtai Central Hospital from July 2019 to July 2022 were selected and divided into a capacity overload group ( n=182) and a non capacity overload group ( n=118) based on their capacity balance level. Two clinical data sets were compared and analyzed. The receiver operating characteristic (ROC) curve was used to analyze the evaluation value of serum PTX3 and CK-MB levels on the volume load of CDHF patients. The clinical disease characteristics of the two groups of patients were analyzed using univariate analysis, and the influencing factors of volume load of CDHF patients were analyzed using logistic regression. A column chart model was constructed and validated. Results:The body mass index (BMI), waist circumference, systolic blood pressure, diastolic blood pressure, fasting blood glucose (FBG), glycosylated hemoglobin (HbA 1c), C-reactive protein (CRP), uric acid (UA), homeostasis model assessment of insulin resistance (HOMA-IR) of patients in the capacity overload group were higher than those in the non-capacity overload group, and the differences were statistically significant (all P<0.05). The PTX3, CK-MB, pulmonary capillary wedge pressure (PCWP), and CVP levels of patients in the capacity overload group were higher than those in the non-capacity overload group, while albumin, hemoglobin, and hematocrit were lower than those in the non-capacity overload group, and the differences were statistically significant (all P<0.05). The ROC curve showed that the area under the curve (AUC) of PTX3 and CK-MB for predicting capacity overload in CDHF patients are 0.795 and 0.718, with sensitivity of 86.2% and 83.7%, specificity of 65.4% and 68.6%, respectively, indicating high predictive accuracy; The AUC of the two joint predictions is 0.817, the sensitivity was 92.5%, and the specificity was 70.6%. The prediction accuracy was higher than PTX3 ( Z=3.812, P<0.05) and CK-MB ( Z=3.365, P<0.05). PTX3, CK-MB, albumin, hemoglobin, hematocrit, PCWP, and central venous pressure (CVP) were all influencing factors of volume load status in CDHF patients (all P<0.05). The column chart risk prediction model established based on these factors had high accuracy and strong applicability in clinical treatment. Conclusions:Serum PTX3 and CK-MB levels are influencing factors for volume overload in CDHF patients. A column chart model constructed in combination with indicators such as albumin, hemoglobin, hematocrit, PCWP, and CVP has high predictive value for the volume overload status of CDHF.
5.Tim4 deficiency reduces CD301b+macrophage and aggravates periodontitis bone loss
Wang ZIMING ; Zeng HAO ; Wang CAN ; Wang JIAOLONG ; Zhang JING ; Qu SHUYUAN ; Han YUE ; Yang LIU ; Ni YUEQI ; Peng WENAN ; Liu HUAN ; Tang HUA ; Zhao QIN ; Zhang YUFENG
International Journal of Oral Science 2024;16(2):280-292
Periodontitis is a common chronic inflammatory disease that causes the periodontal bone destruction and may ultimately result in tooth loss.With the progression of periodontitis,the osteoimmunology microenvironment in periodontitis is damaged and leads to the formation of pathological alveolar bone resorption.CD301b+macrophages are specific to the osteoimmunology microenvironment,and are emerging as vital booster for conducting bone regeneration.However,the key upstream targets of CD301b+macrophages and their potential mechanism in periodontitis remain elusive.In this study,we concentrated on the role of Tim4,a latent upstream regulator of CD301b+macrophages.We first demonstrated that the transcription level of Timd4(gene name of Tim4)in CD301b+macrophages was significantly upregulated compared to CD301b-macrophages via high-throughput RNA sequencing.Moreover,several Tim4-related functions such as apoptotic cell clearance,phagocytosis and engulfment were positively regulated by CD301b+macrophages.The single-cell RNA sequencing analysis subsequently discovered that Cd301b and Timd4 were specifically co-expressed in macrophages.The following flow cytometric analysis indicated that Tim4 positive expression rates in total macrophages shared highly synchronized dynamic changes with the proportions of CD301b+macrophages as periodontitis progressed.Furthermore,the deficiency of Tim4 in mice decreased CD301b+macrophages and eventually magnified alveolar bone resorption in periodontitis.Additionally,Tim4 controlled the p38 MAPK signaling pathway to ultimately mediate CD301b+macrophages phenotype.In a word,Tim4 might regulate CD301b+macrophages through p38 MAPK signaling pathway in periodontitis,which provided new insights into periodontitis immunoregulation as well as help to develop innovative therapeutic targets and treatment strategies for periodontitis.
6.Effect of Sangqiao Qingfei Formula combined with western medicine conventional therapy combined with mechanical ventilation on pulmonary function and serum PCT in patients with AECOPD respiratory failure
Xin YU ; Yufeng ZHANG ; Cong WANG ; Haibing HUA ; Weilong JIANG
International Journal of Traditional Chinese Medicine 2024;46(9):1121-1127
Objective:To explore the effects of Sangqiao Qingfei Prescription combined with Western medicine conventional therapy with mechanical ventilation on lung function and airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) respiratory failure; To evaluate clinical efficacy.Methods:A randomized controlled trial study was conducted. Totally 90 AECOPD patients with respiratory failure in our hospital from January 2020 to December 2022 were selected as the observation subjects. They were divided into two groups using a random number table method, with 45 cases in each group. The control group received mechanical ventilation treatment, while the observation group received Sangqiao Qingfei Prescription on the basis of the control group. Both groups were treated for 2 weeks. TCM syndrome scoring was performed before and after treatment, and the time of successful withdrawal from the machine was recorded; a blood gas analyzer was used to detect PaO 2, PaCO 2, blood oxygen saturation (SaO 2) and pH values; the plateau pressure (Pplat), peak airway pressure (Ppeak), airway resistance (Raw) and dynamic lung compliance (Cdyn) were recorded during the ventilator; a pulmonary function meter was used to measure respiratory rate (RR), maximum expiratory flow (PEF), FVC, FEV1, and the percentage of FEV1 to the estimated value (FEV1% estimated value); serum CRP, TNF-α, and Procalcitonin (PCT) were detected using ELISA method. Clinical efficacy was evaluated. Results:During the treatment period, there were no cases of detachment in both groups. The mechanical ventilation time in the observation group was (7.16 ± 0.69) d, while in the control group it was (9.88 ± 1.04) d, with statistical significance ( t=14.62, P<0.001); after treatment, the main symptom, secondary symptom scores, and total scores of the observation group were lower than those in the control group ( t values of 13.43, 18.53, 31.21, P<0.001); the PaO 2 [(79.16 ± 7.42) mmHg vs. (67.49 ± 6.88) mmHg, t=8.24], SaO 2 [(95.15 ± 9.93)% vs. (84.59 ± 9.48)%, t=5.16], and pH value (7.35 ± 0.23 vs. 7.26 ± 0.16, t=2.16) in the observation group were higher than those in the control group ( P<0.01 or P<0.05), while PaCO 2 [(49.89 ± 3.65) mmHg vs. (62.39 ± 4.27) mmHg, t=14.93] was lower than that of the control group ( P<0.01); after treatment in the observation group, Pplat [(15.31 ± 2.51) cmH 2O vs. (17.53 ± 2.02) cmH 2O, t=4.62], Ppeak [(22.43 ± 3.16) cmH 2O vs. (25.78 ± 3.17) cmH 2O, t=5.02], Raw [(18.96 ± 3.86) cmH 2O/(S?L) vs. (24.29 ± 4.29) cmH 2O/(S?L), t=6.20] were lower than those in the control group ( P<0.01), Cdyn [(34.53 ± 3.35) cmH 2O/(S?L) vs. (30.27 ± 3.87) cmH 2O/(S?L), t=5.58] was higher than the control group ( P<0.01); the RR [(19.25 ± 2.43) times/min vs. (23.49 ± 3.07) times/min, t=7.26] in the observation group was lower than that of the control group ( P<0.01), PEF [(4.99 ± 0.40) L/s vs. (4.03 ± 0.34) L/s, t=12.27], FVC [(3.04 ± 0.20) L vs. (2.14 ± 0.22) L, t=20.31], FEV1 [(2.83 ± 0.20) L vs. (2.16 ± 0.13) L, t=18.84], FEV1% estimated value [(42.23 ± 4.66)% vs. (36.43 ± 5.09)%, t=5.64] were higher than those in the control group ( P<0.01); serum CRP, IL-6, TNF-α and PCT in the observation group were lower than those in the control group ( t values were 18.13, 13.36, 15.97, 30.67, P<0.01). The total effective rate of the observation group was 93.33% (42/45), while that of the control group was 77.78% (35/45), with statistical significance ( χ2=4.41, P=0.036). Conclusion:The combination of Sangqiao Qingfei Prescription and conventional Western medicine treatment with mechanical ventilation can effectively improve lung ventilation function, reduce inflammatory cytokine levels, alleviate inflammatory reactions, and improve clinical efficacy in AECOPD patients with respiratory failure.
7.Maternal liver damage induced by cadmium exposure in pregnant mice through hypoxia inducible factor-1α-mediated upregulation in DRP1
Limin DAI ; Hualong ZHU ; Yongwei XIONG ; Weibo LIU ; Guoxiang ZHOU ; Shuang ZHANG ; Zhengjia LING ; Lulu TAN ; Jin ZHANG ; Yufeng ZHANG ; Yiting FU ; Daixin LI ; Hua WANG
Journal of Environmental and Occupational Medicine 2023;40(1):68-75
Background Mitochondrial dynamin-related protein 1 (DRP1) regulates mitochondrial division and plays an important role in maintaining hepatocyte function. However, the role of DRP1 in cadmium exposure-induced maternal liver damage in pregnant mice remains unclear. Objective To investigate the role and mechanism of DRP1 in maternal liver damage induced by cadmium exposure during pregnancy. Methods This study consisted of animal experiments and cell experiments. (1) Animal experiments. Mice at 14 days of gestation were randomly divided into three groups: a control group, a low-dose cadmium group (LCd group: 2.5 mg·kg−1), and a high-dose cadmium group (HCd group: 5 mg·kg−1). The pregnant mice were intraperitoneally injected with cadmium chloride (CdCl2) for 6 and 24 h in the next morning. The weights of pregnant mice, uterus, maternal liver, and fetal mice were recorded after sacrifice. Serum and liver of pregnant mice were collected, the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum were detected, and liver tissues were stained with HE to observe changes in liver function and liver tissue structure. The expressions of oxidative phosphorylation-related proteins, hypoxia inducible factor-1α (HIF-1α) and DRP1 proteins in liver of pregnant mice were detected by Western blotting. (2) Cell experiments. AML12 cells were treated with CdCl2 (10 μmol·L−1) for 0, 2, 6, 12, and 24 h. The expressions of oxidative phosphorylation-related proteins, DRP1, and hypoxia inducible factor-1α (HIF-1α) proteins were detected. AML12 cells were pretreated with DRP1 inhibitor Mdivi-1 for 1 h and then CdCl2 (10 μmol·L−1) for 12 h to detect the expression of oxidative phosphorylation-related proteins and DRP1 protein. AML12 cells were treated with Hif-1α siRNA for 48 h and CdCl2 (10 μmol·L−1) for 6 h to detect the expression of HIF-1α and DRP1 proteins. Results The results of animal experiments showed that cadmium exposure in pregnant mice had no effects on maternal liver weight and liver coefficient. However, the histomorphological changes and necrosis in hepatocytes were observed. Compared with the control group, the serum ALT and AST levels of pregnant mice in the LCd group were significantly increased after 6 h (P<0.05), and the levels in the HCd group were significantly increased after 6 and 24 h (P<0.05). Cadmium exposure during pregnancy significantly up-regulated HIF-1α and DRP1 expressions and down-regulated the expressions of oxidative phosphorylation-related proteins in maternal livers. In vitro cell experiments showed that the expressions of oxidative phosphorylation-related proteins was significantly decreased and HIF-1α and DRP1 protein expressions were significantly increased in the AML12 cells treated with CdCl2 for 6 h. Mdivi-1 pretreatment significantly antagonized the inhibitory effect of cadmium on the expressions of oxidative phosphorylation-related proteins in AML12 cells, while Hif-1α siRNA pretreatment significantly antagonized the up-regulative effect of cadmium on DRP1 expression in AML12 cells. Conclusion Cadmium exposure in pregnant mice may up-regulate DRP1 expression by activating HIF-1α signaling, then inhibit oxidative phosphorylation level of hepatic cells, and ultimately lead to maternal liver damage.
8.CD301b+ macrophage: the new booster for activating bone regeneration in periodontitis treatment.
Can WANG ; Qin ZHAO ; Chen CHEN ; Jiaojiao LI ; Jing ZHANG ; Shuyuan QU ; Hua TANG ; Hao ZENG ; Yufeng ZHANG
International Journal of Oral Science 2023;15(1):19-19
Periodontal bone regeneration is a major challenge in the treatment of periodontitis. Currently the main obstacle is the difficulty of restoring the regenerative vitality of periodontal osteoblast lineages suppressed by inflammation, via conventional treatment. CD301b+ macrophages were recently identified as a subpopulation that is characteristic of a regenerative environment, but their role in periodontal bone repair has not been reported. The current study indicates that CD301b+ macrophages may be a constituent component of periodontal bone repair, and that they are devoted to bone formation in the resolving phase of periodontitis. Transcriptome sequencing suggested that CD301b+ macrophages could positively regulate osteogenesis-related processes. In vitro, CD301b+ macrophages could be induced by interleukin 4 (IL-4) unless proinflammatory cytokines such as interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) were present. Mechanistically, CD301b+ macrophages promoted osteoblast differentiation via insulin-like growth factor 1 (IGF-1)/thymoma viral proto-oncogene 1 (Akt)/mammalian target of rapamycin (mTOR) signaling. An osteogenic inducible nano-capsule (OINC) consisting of a gold nanocage loaded with IL-4 as the "core" and mouse neutrophil membrane as the "shell" was designed. When injected into periodontal tissue, OINCs first absorbed proinflammatory cytokines in inflamed periodontal tissue, then released IL-4 controlled by far-red irradiation. These events collectively promoted CD301b+ macrophage enrichment, which further boosted periodontal bone regeneration. The current study highlights the osteoinductive role of CD301b+ macrophages, and suggests a CD301b+ macrophage-targeted induction strategy based on biomimetic nano-capsules for improved therapeutic efficacy, which may also provide a potential therapeutic target and strategy for other inflammatory bone diseases.
Animals
;
Mice
;
Bone Regeneration
;
Cytokines/metabolism*
;
Interleukin-4/therapeutic use*
;
Macrophages/physiology*
;
Mammals
;
Osteogenesis
;
Periodontitis/drug therapy*
9.Clinical treatment guideline for pulmonary blast injury (version 2023)
Zhiming SONG ; Junhua GUO ; Jianming CHEN ; Jing ZHONG ; Yan DOU ; Jiarong MENG ; Guomin ZHANG ; Guodong LIU ; Huaping LIANG ; Hezhong CHEN ; Shuogui XU ; Yufeng ZHANG ; Zhinong WANG ; Daixing ZHONG ; Tao JIANG ; Zhiqiang XUE ; Feihu ZHOU ; Zhixin LIANG ; Yang LIU ; Xu WU ; Kaican CAI ; Yi SHEN ; Yong SONG ; Xiaoli YUAN ; Enwu XU ; Yifeng ZHENG ; Shumin WANG ; Erping XI ; Shengsheng YANG ; Wenke CAI ; Yu CHEN ; Qingxin LI ; Zhiqiang ZOU ; Chang SU ; Hongwei SHANG ; Jiangxing XU ; Yongjing LIU ; Qianjin WANG ; Xiaodong WEI ; Guoan XU ; Gaofeng LIU ; Junhui LUO ; Qinghua LI ; Bin SONG ; Ming GUO ; Chen HUANG ; Xunyu XU ; Yuanrong TU ; Liling ZHENG ; Mingke DUAN ; Renping WAN ; Tengbo YU ; Hai YU ; Yanmei ZHAO ; Yuping WEI ; Jin ZHANG ; Hua GUO ; Jianxin JIANG ; Lianyang ZHANG ; Yunfeng YI
Chinese Journal of Trauma 2023;39(12):1057-1069
Pulmonary blast injury has become the main type of trauma in modern warfare, characterized by externally mild injuries but internally severe injuries, rapid disease progression, and a high rate of early death. The injury is complicated in clinical practice, often with multiple and compound injuries. Currently, there is a lack of effective protective materials, accurate injury detection instrument and portable monitoring and transportation equipment, standardized clinical treatment guidelines in various medical centers, and evidence-based guidelines at home and abroad, resulting in a high mortality in clinlcal practice. Therefore, the Trauma Branch of Chinese Medical Association and the Editorial Committee of Chinese Journal of Trauma organized military and civilian experts in related fields such as thoracic surgery and traumatic surgery to jointly develop the Clinical treatment guideline for pulmonary blast injury ( version 2023) by combining evidence for effectiveness and clinical first-line treatment experience. This guideline provided 16 recommended opinions surrounding definition, characteristics, pre-hospital diagnosis and treatment, and in-hospital treatment of pulmonary blast injury, hoping to provide a basis for the clinical treatment in hospitals at different levels.
10.Promoting the exploration and research of hospital patent transformation through multiple channels
Qian HUA ; Junyang CHEN ; Ziyan ZHU ; Jing JIN ; Yufeng HUANG ; Leilei CHENG
Chinese Journal of Medical Science Research Management 2022;35(2):127-130
Objective:The medical-related patent transformation level is relatively low in China for a long time. However, with the support and advancement of a series of national policies, domestic patents and other medical intellectual property projects are increasing year by year, and medical transformation is also receiving more and more attention. Zhongshan Hospital affiliated to Fudan University actively promotes the transformation of hospital patents through various channels, and actively explores how to carry out patent transformation and how to improve the success rate of transformation. This article aims to analyze and explore the feasibility of multi-channel promotion of patents, and to open up a new path for the use of new media to promote patent conversion.Methods:Through Excel analysis of " Zhongshan Patent Hero Post" WeChat public account and official Weibo platform weekly page views data and patent salon project data, as well as the patent application and transformation of Zhongshan Hospital in the past 6 years, and analyze the effect of patent promotion.Results:Through multiple channels and various links of effective promotion methods, the patent application and conversion situation of Zhongshan Hospital has doubled in the past 6 years.Conclusions:The hospital will further actively explore the patent application and transformation process, the full-cycle promotion method of each link, and provide a transfer and transformation consulting docking and promotion platform for the scientific research results or patent technologies related to hospitals and enterprises, and help the transformation of medical patents.

Result Analysis
Print
Save
E-mail